Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) Shares Outstanding (Weighted Average) (2016 - 2024)

Historic Shares Outstanding (Weighted Average) for Immucell (ICCC) over the last 15 years, with Q2 2024 value amounting to $7.8 million.

  • Immucell's Shares Outstanding (Weighted Average) rose 81.55% to $7.8 million in Q2 2024 from the same period last year, while for Jun 2024 it was $7.8 million, marking a year-over-year increase of 81.55%. This contributed to the annual value of $7.7 million for FY2023, which is 3.31% up from last year.
  • Latest data reveals that Immucell reported Shares Outstanding (Weighted Average) of $7.8 million as of Q2 2024, which was up 81.55% from $7.7 million recorded in Q4 2023.
  • In the past 5 years, Immucell's Shares Outstanding (Weighted Average) ranged from a high of $7.8 million in Q2 2024 and a low of $7.2 million during Q1 2020
  • Over the past 5 years, Immucell's median Shares Outstanding (Weighted Average) value was $7.7 million (recorded in 2022), while the average stood at $7.6 million.
  • As far as peak fluctuations go, Immucell's Shares Outstanding (Weighted Average) soared by 2824.1% in 2020, and later changed by 0.0% in 2023.
  • Immucell's Shares Outstanding (Weighted Average) (Quarter) stood at $7.2 million in 2020, then increased by 5.25% to $7.6 million in 2021, then grew by 2.01% to $7.7 million in 2022, then grew by 0.03% to $7.7 million in 2023, then increased by 0.8% to $7.8 million in 2024.
  • Its Shares Outstanding (Weighted Average) stands at $7.8 million for Q2 2024, versus $7.7 million for Q4 2023 and $7.7 million for Q3 2023.